P. Hiemstra (Leiden, Netherlands), M. Platé (London, United Kingdom)
Late Breaking Abstract - Mapping fibroblast activity in IPF– the instructive lung ECM
A. Löfdahl (Lund, Sweden), L. Elowsson Rendin (Lund, Sweden), X. Zhou (Gothenburg, Sweden), G. Dellgren (Gothenburg, Sweden), M. Silverborn (Gothenburg, Sweden), L. Bjermer (Lund, Sweden), G. Westergren-Thorsson (Lund, Sweden)
|   |
Late Breaking Abstract - Copper-heparin counteracts elastase-induced emphysema formation
I. Piscaer (Maastricht, Netherlands), L. Kistemaker (Groningen, Netherlands), R. Gosens (Groningen, Netherlands), F. Franssen (Maastricht, Netherlands), E. Wouters (Maastricht, Netherlands), H. Frijlink (Groningen, Netherlands), R. Janssen (Nijmegen, Netherlands)
| |
Modelling alveoli on a breathing lung-on-chip in health and disease
C. Richter (Saarbrücken, Germany), A. Hidalgo (Saarbrücken, Germany), P. Carius (Saarbrücken, Germany), N. Roldan (Bern, Switzerland), J. Stucki (Bern, Switzerland), N. Hobi (Bern, Switzerland), N. Schneider-Daum (Saarbrücken, Germany), C. Lehr (Saarbrücken, Germany)
| |
Modeling alveolar barrier disruption in vitro for sepsis-induced ARDS preclinical studies
N. Roldan (Bern, Switzerland), G. Raggi (Bern, Switzerland), K. Fytianos (Bern, Switzerland), J. Petracca (Bern, Switzerland), J. Stucki (Bern, Switzerland), F. Käsermann (Bern, Switzerland), N. Hobi (Bern, Switzerland)
| |
Combined cell therapy and anticoagulants for acute respiratory distress syndrome
M. Camprubí-Rimblas (Sabadell, Spain), A. Areny (Sabadell, Spain), R. Guillamat-Prats (Sabadell, Spain), L. Morales-Quinteros (Sabadell, Spain), N. Tantinyà (Sabadell, Spain), J. Bringué (Sabadell, Spain), L. Blanch (Sabadell, Spain), A. Artigas (Sabadell, Spain)
| |
LSC - 2020 - pSTAT5-SOCS1 signalling as a novel pathway in macrophage metabolic reprogramming by Mesenchymal Stromal Cells (MSCs) in ARDS
Y. Su (Belfast (Northern Ireland), United Kingdom)
| |
Intratracheal application of healthy lung derived Mesenchymal Stem Cells (DON-MSC) in the form of biospheres (BS) as potential therapeutic agents for chronic lung disease
A. Jahn (Palma De Mallorca, Spain), C. Rio (Palma De Mallorca, Spain), A. Martin-Medina (Palma De Mallorca, Spain), A. Igleasias Coma (Palma De Mallorca, Spain), J. Mercader Barceló (Palma De Mallorca, Spain), O. Gigirey (Palma De Mallorca, Spain), C. Villena (Palma De Mallorca, Spain), E. Sala Linas (Palma De Mallorca, Spain)
| |
CCR2:A potential target for lung injury resolution>
A. Villabona-Rueda (Baltimore, United States of America), Q. Zhong (Baltimore, United States of America), Y. Xiong (Baltimore, United States of America), T. Palmer (Baltimore, United States of America), F. D'Alessio (Baltimore, United States of America)
| |
Azithromycin maintains barrier integrity in a cell model of ventilator induced lung injury
J. Joelsson (Reykjavik, Iceland), I. Myszor (Reykjavik, Iceland), S. Sigurdsson (Reykjavik, Iceland), F. Lehmann (Reykjavik, Iceland), C. Page (London, United Kingdom), G. Gudmundsson (Reykjavik, Iceland), T. Gudjonsson (Reykjavik, Iceland), S. Karason (Reykjavik, Iceland)
| |
Transforming growth factor beta (TGF-ß) pathway activation by IPF fibroblast-derived soluble factors is mediated by IL-6 trans-signaling
G. Epstein Shochet (Kfar-Saba, Israel), B. Bardenstein-Wald (Tel Aviv, Israel), E. Brook (Tel Aviv, Israel), D. Shitrit (Tel Aviv, Israel)
| |
Growth hormone releasing hormone-receptor antagonist MIA-602 modulates lung inflammation, cellular signal transduction, and promotes apoptosis of mouse lung fibroblasts
J. Zhang (Miami, United States of America), R. Cui (Miami, United States of America), T. Runxia (Miami, United States of America), R. Cai (Miami, United States of America), M. Mirsaeidi (Miami, United States of America), A. Schally (Miami, United States of America), R. Jackson (Miami, United States of America)
| |
6-aminonicotinamide ameliorates pulmonary fibrosis by suppressing the TGF-beta1 activated Smad signalling pathway
M. KIM (Seoul, Republic of Korea), H. Kim (Seoul, Republic of Korea), S. Moon (Seoul, Republic of Korea), H. Yoo (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea)
| |
Antifibrotics effects of nintedanib on lung fibroblasts derived from patients with progressive fibrosing intertitial lung diseases
A. Joannes (Rennes, France), C. Morzadec (Rennes, France), F. Llamas Gutierrez (Rennes, France), D. Chiforeanu (Rennes, France), B. Richard De Latour (Rennes, France), L. Wollin (Biberach an der Riss, Germany), S. Jouneau (Rennes, France), L. Vernhet (Rennes, France)
| |
Profibrotic implication of platelet-activating factor in tuberculous pleural effusion
C. Chung (Taipei, Taiwan), M. Chen (Taipei, Taiwan), J. Tsai (Taipei, Taiwan), C. Hsieh (Taipei, Taiwan)
| |
SDF-1 is an antifibrotic mediator in vivo
A. Gazdhar (Bern, Switzerland), K. Fytianos (Bern, Switzerland), R. Schliep (Bern, Switzerland), S. Mykoniati ( Delemont,, Switzerland), P. Khan (Basel, Switzerland), K. Hostettler (Basel, Switzerland), L. Knudsen (Hanover , Germany), T. Geiser (Hanover, Germany)
| |
FGFR4 has pro fibrotic properties in Idiopathic Pulmonary Fibrosis
A. Justet (Paris, France), M. Ghanem (Paris, France), M. Jaillet (Paris, France), M. Hachem (Paris, France), T. Boghanim (Paris, France), A. Vadel (Paris, France), A. Mailleux (Paris, France), B. Crestani (Paris, France)
| |
Fibrosis-specific stem-like cells in peripheral IPF lung: Characteristics and potential role
P. Khan (Basel, Switzerland), J. Roux (Basel, Switzerland), S. Savic (Basel, Switzerland), L. Knudsen (Hannover, Germany), D. Jonigk (Hannover, Germany), M. Kuehnel (Hannover, Germany), A. Gazdhar (Bern, Switzerland), T. Geiser (Bern, Switzerland), M. Tamm (Basel, Switzerland), K. Hostettler (Basel, Switzerland)
| |
LSC - 2020 - The transcriptome of IPF fibrotic foci identifies the fatty acid metabolism as a critical pathway in fibrogenesis
| |